Haemostasis

• Healthcare Professionals
•  
• Patients
•  
• Investors
•  
• Media
•  
• R&D
•  
• Jobs
•  
• Sustainability
•  
• About us

• R&D at a glance
• About R&D
• Pipeline
• Partnering
  • Why partner with us?
  • Diabetes
  • Protein Delivery
  • Haemophilia
  • Growth disorders
  • Inflammation
  • Partnerships
  • Protein expertise
  • Clinical research partnerships
  • Novo Nordisk Biotech Fund
  • Contact us
• Scientific publications
• Bioethics
• From idea to patient
• Fellowships
• Novo Nordisk Trials
• Contact us

• Rate this page
• Send to a friend
• Print

Haemophilia

We seek new innovations for:

• preventing and treating bleeding in people with haemophilia with and without inhibitors
• preventing and treating critical bleedings and their consequences.

Our position

Our discovery of recombinant human Factor VIIa (rFVIIa), a coagulation protein and the active substance in NovoSeven®, set us on our pioneering path within haemostatic agents. Within coagulation and haemostasis we have long-standing expertise in various in vitro and in vivo models as well as in clinical development.

We are now the leader in the global haemophilia inhibitor segment.

Biopharmaceuticals Research Unit

Contact

For further information please contact Biopharmaceuticals Sourcing

Download

Please download the Novo Nordisk:
Partnering folder
Nature partnering add

Back to top